DEXMEDETOMIDINE HYDROCHLORIDE (dexmedetomidine) by R-Pharm US is 2 -adrenergic agonist with sedative properties. First approved in 2015.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
Dexmedetomidine is a selective alpha-2 adrenergic agonist administered intravenously as a solution for sedation in clinical settings. It works through alpha-2 receptor activation to produce sedative and analgesic effects, with dose-dependent engagement of alpha-1 receptors at higher doses. The drug is primarily used for procedural sedation and ICU sedation in hospital and perioperative environments.
Product is at peak commercial maturity with established market penetration; team focus is likely on optimization and maintaining market position rather than growth initiatives.
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity was observed in animals following slow intravenous infusion of low and medium doses (10 mcg/kg to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (greater than or equal…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery
Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Worked on DEXMEDETOMIDINE HYDROCHLORIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on dexmedetomidine offers stable, mature-product experience with deep healthcare relationships in ICU and perioperative settings rather than growth-stage innovation. Career trajectory emphasizes clinical credibility, health system navigation, and defending market position against potential future competition.